$25.70
−0.43%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$26.26
From 52W high−25.38%
Volume887483.00
Market cap$2.89B
P/E (TTM)—
P/S (TTM)6.4x
Div yield—
Key dataSep 18, 2026
Open
$26.26
From 52W high
−25.38%
Volume
887483.00
Market cap
$2.89B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.9x
P/E (TTM)
—
RSI (14)
58.5
MomentumView details →
1D Return
−0.43%
YTD Return
+46.93%
SummaryUpdated Jun 1, 2026
Zai Lab Limited (NASDAQ:ZLAB) is a Chinese biopharmaceutical company founded in 2013 and headquartered in Shanghai. The company went public on NASDAQ in September 2017. Zai Lab has evolved from a pure licensing and development company into a commercial-stage biopharmaceutical enterprise with a growing portfolio of marketed products and an extensive pipeline of investigational therapies. The company focuses primarily on bringing innovative medicines to patients in China and other Asian markets, while also developing select assets for global markets.
Similar companies
Latest newsMore news →
Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.42d agoZai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.45d agoThe U.S. FDA granted Orphan Drug Designation to Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas.48d ago